{"id":2618,"date":"2026-08-18T09:00:00","date_gmt":"2026-08-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2618"},"modified":"2026-08-19T18:19:56","modified_gmt":"2026-08-19T22:19:56","slug":"abcuro-raises-66-million-to-fund-second-registrational-attempt-in-inclusion-body-myositis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2618","title":{"rendered":"Abcuro Raises $66 Million to Fund Second Registrational Attempt in Inclusion-Body Myositis"},"content":{"rendered":"

Company:<\/strong> Abcuro · Event Type:<\/strong> Series D Financing · Product:<\/strong> Ulviprubart (ABC008) · Mechanism:<\/strong> Anti-KLRG1 Monoclonal Antibody · Indication:<\/strong> Inclusion-Body Myositis · Announcement Date:<\/strong> August 18, 2026<\/p>\n

\"Abcuro<\/p>\n

Summary<\/h4>\n

Abcuro closed a $66 million Series D financing to fund a new, potentially registrational study of ulviprubart in people with less severe inclusion-body myositis (IBM). New Leaf Venture Partners led the round, with Rock Springs Capital joining as a new investor alongside existing backers. The company plans to begin the study in the fourth quarter of 2026, with topline data expected in the second half of 2028. The financing follows the 272-patient MUSCLE Phase II\/III trial, which missed its primary and key secondary endpoints in the overall population. A prespecified higher-function subgroup showed roughly 50% slower functional decline, but the reported dose-specific p values of 0.066 and 0.075 did not reach nominal statistical significance. The new capital funds a rational enrichment hypothesis, not a validated pivotal result.<\/p>\n

What Happened<\/h4>\n

The Series D funds the subgroup-focused study plus corporate operations. Abcuro says it has discussed the program with the FDA and that a positive study could support a biologics license application, though it did not disclose protocol, sample size, endpoint hierarchy, alpha control, or use-of-proceeds allocation.<\/p>\n

MUSCLE was randomized, double-blind and placebo-controlled, enrolling adults with IBM across two ulviprubart doses. The full population did not meet the functional primary endpoint or key secondary endpoints. In a prespecified subgroup with higher baseline IBM Functional Rating Scale (IBMFRS) scores, the company reported about 50% slower decline versus placebo. One disclosure described the threshold as “at least 29” and the financing release described it as “greater than 29” — an inconsistency that should be resolved in the new protocol.<\/p>\n

Deep Analysis<\/h4>\n

Ulviprubart is designed to selectively deplete KLRG1-positive differentiated cytotoxic T cells implicated in muscle-fiber injury while sparing other immune populations. The mechanistic thesis is attractive in IBM, where cytotoxic lymphocytes infiltrate muscle and no approved pharmacologic treatment has altered progression. Selective depletion may avoid broader immunosuppression, but the relative contribution of degenerative versus immune biology to disease progression remains an open question.<\/p>\n

The subgroup hypothesis is biologically plausible: advanced disease may contain less reversible muscle loss and a lower ceiling for immune intervention to show benefit. Prespecification reduces but does not eliminate false-positive risk, and the subgroup result did not reach nominal statistical significance at either dose. Enrichment strategies can also magnify regression to the mean, endpoint variability, or baseline imbalance — a new, independently powered study with a prospectively locked threshold is required to resolve this.<\/p>\n

Safety in MUSCLE was described as favorable, with more falls, chills, headache, fever and nasopharyngitis reported in treated groups and no discontinuations attributed to treatment-emergent adverse events. That record supports continued testing but does not establish long-term infection or immune-surveillance safety in an enriched, longer-duration population.<\/p>\n

Company and Product Background<\/h4>\n

Abcuro is a private, clinical-stage biotechnology company focused on diseases driven by cytotoxic T cells. Ulviprubart, formerly ABC008, is a monoclonal antibody directed at KLRG1; the company is also studying it in T-cell large granular lymphocytic leukemia. IBM is a progressive adult-onset inflammatory and degenerative myopathy affecting the quadriceps, finger flexors and swallowing musculature, with no approved disease-modifying therapy.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Signal<\/th>\nVerified Evidence<\/th>\nCurrent Limit<\/th>\n<\/tr>\n
Financing<\/td>\n$66 million Series D closed; New Leaf led<\/td>\nValuation, tranche terms and runway undisclosed<\/td>\n<\/tr>\n
Use of proceeds<\/td>\nNew potentially registrational subgroup-focused study<\/td>\nProtocol, sample size and regulatory alignment undisclosed<\/td>\n<\/tr>\n
Prior trial<\/td>\nMUSCLE missed primary and key secondary endpoints overall<\/td>\nFull peer-reviewed dataset not yet available<\/td>\n<\/tr>\n
Subgroup<\/td>\n~50% slower decline in prespecified higher-function patients<\/td>\np=0.066 and p=0.075; threshold described inconsistently<\/td>\n<\/tr>\n
Catalysts<\/td>\nStudy start planned Q4 2026; topline planned 2H 2028<\/td>\nTiming and enrollment execution remain prospective<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> The financing enables a statistically cleaner confirmation of a biologically credible earlier-disease effect. Subgroup prespecification, consistent directional results across doses, high unmet need and continued investor participation all support this reading. A prospectively enriched randomized trial with replicated functional effect and acceptable safety would upgrade the thesis.<\/p>\n

Bear case:<\/strong> The round extends a program around a fragile subgroup signal that may not reproduce. The overall trial miss, borderline subgroup p values, threshold inconsistency and a two-year readout horizon all support this reading. Protocol drift or another null result would confirm this concern.<\/p>\n

InSilens Take<\/h4>\n

This is a 4\/5 mixed financing signal. The round is material because it funds a second potentially registrational attempt in a disease without approved pharmacologic therapy, but capital commitment does not validate the subgroup. The next upgrade is a public protocol with an unambiguous threshold, statistical control and regulator-supported endpoint strategy. The decisive falsifier is failure to replicate functional preservation in the prospectively enriched population.<\/p>\n

Signal Assessment<\/h4>\n

Signal Importance:<\/strong> 4\/5 — $66 million funds a potentially registrational retry in a high-unmet-need disease.
\nSignal Direction:<\/strong> Mixed — new capital and a prespecified hypothesis offset by an overall trial miss.
\nConfidence in Facts:<\/strong> High — financing, registry and company trial disclosures align.
\nConfidence in Interpretation:<\/strong> Moderate — protocol, FDA alignment, subgroup reproducibility and runway are unknown.<\/p>\n","protected":false},"excerpt":{"rendered":"

Abcuro closed a $66 million Series D financing to fund a new, potentially registrational study of ulviprubart in people with less severe inclusion-body myositis (IBM). New Leaf Venture Partners led the round, with Rock…<\/p>\n","protected":false},"author":1,"featured_media":2622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[387,389,388],"class_list":["post-2618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-abcuro","tag-inclusion-body-myositis","tag-ulviprubart"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2618"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2618\/revisions"}],"predecessor-version":[{"id":2627,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2618\/revisions\/2627"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2622"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}